Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company's commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:XENT
- CUSIP: N/A
- Web: www.intersectent.com
Capitalization:- Market Cap: $802.74 million
- Outstanding Shares: 28,772,000
Average Prices:- 50 Day Moving Avg: $27.22
- 200 Day Moving Avg: $19.28
- 52 Week Range: $7.65 - $29.55
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -59.36
- P/E Growth: -1.93
Sales & Book Value:- Annual Revenue: $82.49 million
- Price / Sales: 9.73
- Book Value: $3.83 per share
- Price / Book: 7.28
Profitability:- EBIDTA: ($23,420,000.00)
- Net Margins: -28.71%
- Return on Equity: -20.49%
- Return on Assets: -18.29%
Debt:- Current Ratio: 9.47%
- Quick Ratio: 8.90%
Misc:- Average Volume: 421,359 shs.
- Beta: 0.78
- Short Ratio: 1.43
Frequently Asked Questions for Intersect ENT (NASDAQ:XENT)
What is Intersect ENT's stock symbol?
Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."
How were Intersect ENT's earnings last quarter?
Intersect ENT, Inc. (NASDAQ:XENT) released its quarterly earnings data on Tuesday, May, 2nd. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.02. The company had revenue of $20.47 million for the quarter, compared to analysts' expectations of $19.39 million. Intersect ENT had a negative net margin of 28.71% and a negative return on equity of 20.49%. View Intersect ENT's Earnings History.
Where is Intersect ENT's stock going? Where will Intersect ENT's stock price be in 2017?
10 brokers have issued 1-year price targets for Intersect ENT's shares. Their predictions range from $14.00 to $26.00. On average, they anticipate Intersect ENT's stock price to reach $18.78 in the next year. View Analyst Ratings for Intersect ENT.
What are analysts saying about Intersect ENT stock?
Here are some recent quotes from research analysts about Intersect ENT stock:
- 1. According to Zacks Investment Research, "Intersect ENT, Inc. is a commercial drug-device company. The Company's initial products, PROPEL and PROPEL mini, are drug-eluting implants for use in patients with chronic sinusitis. It offers products and therapies for ear, nose, and throat surgeons to improve treatment for their patients with chronic diseases. Intersect ENT, Inc. is headquartered in Menlo Park, California. " (7/5/2017)
- 2. Northland Securities analysts commented, "We remain bullish on the takeout potential of this story. Key Points As a reminder, RESOLVE would be in an office" setting, hence would not be subject to the facility payment pressures currently being witnessed by PROPEL on the Medicare front. It is our understanding that the company would advocate the use of an unlisted J-code (physician administered drug) immediately after NDA approval." (3/13/2017)
Who are some of Intersect ENT's key competitors?
Some companies that are related to Intersect ENT include CONMED Corporation (CNMD), Asante Solutions (PUMP), Cardiovascular Systems (CSII), K2M Group Holdings (KTWO), OraSure Technologies (OSUR), Orthofix International N.V. (OFIX), AtriCure (ATRC), CryoLife (CRY), Meridian Bioscience (VIVO), Consort Medical plc (CSRT), Landauer (LDR), Antares Pharma (ATRS), Exactech (EXAC), Invacare Corporation (IVC), STAAR Surgical Company (STAA), Syneron Medical (ELOS), Sientra (SIEN) and Ocular Therapeutix (OCUL).
Who are Intersect ENT's key executives?
Intersect ENT's management team includes the folowing people:
- Lisa D. Earnhardt, President, Chief Executive Officer, Director
- Jeryl L. Hilleman, Chief Financial Officer
- Richard E. Kaufman, Senior Vice President, Chief Operating Officer
- David A. Lehman, General Counsel
- Gwen Carscadden, Chief People Officer
- Kieran T. Gallahue, Lead Director
- William Anthony Vernon, Director
- Cynthia L. Lucchese, Independent Director
- Dana G. Mead Jr., Independent Director
- Frederic H. Moll M.D., Independent Director
How do I buy Intersect ENT stock?
Shares of Intersect ENT can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intersect ENT's stock price today?
One share of Intersect ENT stock can currently be purchased for approximately $27.90.
MarketBeat Community Rating for Intersect ENT (NASDAQ XENT)MarketBeat's community ratings are surveys of what our community members think about Intersect ENT and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Intersect ENT (NASDAQ:XENT) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Hold Ratings, 7 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.70) |
| Consensus Price Target: | $18.78 (32.70% downside) |
Analysts' Ratings History for Intersect ENT (NASDAQ:XENT)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/31/2017 | Northland Securities | Downgrade | Outperform -> Market Perform | | Medium |  |
| 5/10/2017 | William Blair | Reiterated Rating | Outperform | | Low | |
| 5/3/2017 | Canaccord Genuity | Reiterated Rating | Buy | | High | |
| 5/3/2017 | Wedbush | Boost Price Target | Outperform -> Outperform | $25.00 -> $26.00 | High | |
| 3/6/2017 | Deutsche Bank AG | Upgrade | Hold -> Buy | $15.00 -> $19.00 | N/A | |
| 12/6/2016 | Guggenheim | Initiated Coverage | Buy | $20.00 | N/A | |
| 11/4/2016 | Leerink Swann | Reiterated Rating | Outperform | $21.00 -> $14.00 | N/A | |
| 11/2/2016 | J P Morgan Chase & Co | Downgrade | Overweight -> Neutral | $25.00 -> $16.00 | N/A | |
| 8/26/2016 | Piper Jaffray Companies | Reiterated Rating | Overweight | $21.00 | N/A | |
| 8/4/2016 | BTIG Research | Reiterated Rating | Hold | $14.00 | N/A | |
| 3/24/2016 | Cantor Fitzgerald | Reiterated Rating | Buy | $29.00 | N/A | |
| 12/18/2015 | Bank of America Corporation | Initiated Coverage | Buy | $26.00 | N/A | |
| 10/2/2015 | Sterne Agee CRT | Reiterated Rating | Buy | $37.00 | N/A | |
(Data available from 7/22/2015 forward)
Earnings History for Intersect ENT (NASDAQ:XENT)Earnings History by Quarter for Intersect ENT (NASDAQ XENT)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/2/2017 | Q1 2017 | ($0.25) | ($0.23) | $19.39 million | $20.47 million | View | Listen | |
| 2/28/2017 | Q416 | ($0.20) | ($0.17) | $23.47 million | $24.20 million | View | Listen | |
| 11/2/2016 | Q316 | ($0.27) | ($0.22) | $17.80 million | $18.50 million | View | N/A | |
| 8/2/2016 | Q216 | ($0.26) | ($0.21) | $18.91 million | $19.30 million | View | N/A | |
| 5/5/2016 | Q116 | ($0.29) | ($0.29) | $16.92 million | $16.69 million | View | N/A | |
| 2/23/2016 | Q415 | ($0.25) | ($0.20) | $18.36 million | $18.80 million | View | Listen | |
| 11/4/2015 | Q315 | ($0.29) | ($0.35) | $14.80 million | $14.20 million | View | N/A | |
| 8/5/2015 | Q215 | ($0.26) | ($0.23) | $14.74 million | $15.20 million | View | N/A | |
| 5/6/2015 | Q115 | ($0.33) | ($0.23) | $13.00 million | $13.37 million | View | N/A | |
| 2/26/2015 | Q414 | ($0.29) | ($0.16) | $12.20 million | $13.40 million | View | N/A | |
| 11/5/2014 | Q314 | ($0.35) | ($0.32) | $8.20 million | $9.10 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Intersect ENT (NASDAQ:XENT)2017 EPS Consensus Estimate: ($0.73)
2018 EPS Consensus Estimate: ($0.52)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | ($0.26) | ($0.22) | ($0.24) |
| Q2 2017 | 3 | ($0.19) | ($0.19) | ($0.19) |
| Q3 2017 | 3 | ($0.24) | ($0.14) | ($0.20) |
| Q4 2017 | 3 | ($0.14) | ($0.06) | ($0.11) |
| Q1 2018 | 1 | ($0.17) | ($0.17) | ($0.17) |
| Q2 2018 | 1 | ($0.13) | ($0.13) | ($0.13) |
| Q3 2018 | 1 | ($0.14) | ($0.14) | ($0.14) |
| Q4 2018 | 1 | ($0.08) | ($0.08) | ($0.08) |
(Data provided by Zacks Investment Research)
Dividend History for Intersect ENT (NASDAQ:XENT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Intersect ENT (NASDAQ:XENT)Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 76.12%
Insider Trades by Quarter for Intersect ENT (NASDAQ:XENT)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/17/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $29.03 | $580,600.00 | |
| 7/10/2017 | Jeryl L Hilleman | CFO | Sell | 12,835 | $27.18 | $348,855.30 | |
| 6/15/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $26.10 | $522,000.00 | |
| 5/22/2017 | Richard E Kaufman | COO | Sell | 20,000 | $22.87 | $457,400.00 | |
| 5/15/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $22.98 | $459,600.00 | |
| 4/20/2017 | Richard E Kaufman | COO | Sell | 1,250 | $17.25 | $21,562.50 | |
| 4/17/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $16.06 | $321,200.00 | |
| 3/15/2017 | Lisa D Earnhardt | Insider | Sell | 20,000 | $15.02 | $300,400.00 | |
| 10/20/2016 | Richard E Kaufman | COO | Sell | 3,603 | $16.58 | $59,737.74 | |
| 10/17/2016 | Lisa D Earnhardt | Insider | Sell | 400 | $18.00 | $7,200.00 | |
| 9/7/2016 | Amy Wolbeck | VP | Sell | 28,664 | $15.83 | $453,751.12 | |
| 9/6/2016 | James Stambaugh | VP | Sell | 4,000 | $16.00 | $64,000.00 | |
| 8/3/2016 | James Stambaugh | VP | Sell | 3,977 | $17.00 | $67,609.00 | |
| 7/18/2016 | James Stambaugh | VP | Sell | 5,000 | $15.33 | $76,650.00 | |
| 6/13/2016 | James Stambaugh | VP | Sell | 500 | $14.38 | $7,190.00 | |
| 5/16/2016 | Kieran Gallahue | Director | Buy | 8,000 | $12.64 | $101,120.00 | |
| 4/27/2016 | Amy Wolbeck | VP | Sell | 2,000 | $20.01 | $40,020.00 | |
| 4/20/2016 | Richard E Kaufman | COO | Sell | 3,603 | $18.86 | $67,952.58 | |
| 4/18/2016 | Lisa D Earnhardt | CEO | Sell | 28,500 | $18.69 | $532,665.00 | |
| 3/21/2016 | Richard E Kaufman | COO | Sell | 3,603 | $16.51 | $59,485.53 | |
| 3/15/2016 | Lisa D Earnhardt | CEO | Sell | 9,000 | $18.01 | $162,090.00 | |
| 3/14/2016 | Frederic H Moll | Director | Sell | 1,299 | $18.53 | $24,070.47 | |
| 3/8/2016 | Frederic H Moll | Director | Sell | 601 | $18.56 | $11,154.56 | |
| 2/22/2016 | Richard E Kaufman | COO | Sell | 3,603 | $18.65 | $67,195.95 | |
| 1/21/2016 | Richard E. Kaufman | COO | Sell | 7,206 | $17.93 | $129,203.58 | |
| 1/15/2016 | Lisa D. Earnhardt | CEO | Sell | 12,500 | $19.26 | $240,750.00 | |
| 12/15/2015 | Lisa D Earnhardt | CEO | Sell | 6,820 | $19.85 | $135,377.00 | |
| 11/16/2015 | Lisa D Earnhardt | CEO | Sell | 6,818 | $18.00 | $122,724.00 | |
| 10/15/2015 | Lisa D Earnhardt | CEO | Sell | 6,818 | $18.72 | $127,632.96 | |
| 9/15/2015 | Lisa D Earnhardt | CEO | Sell | 6,818 | $25.99 | $177,199.82 | |
| 9/11/2015 | Frederic H Moll | Director | Sell | 10,000 | $25.21 | $252,100.00 | |
| 8/17/2015 | Lisa D Earnhardt | CEO | Sell | 6,818 | $28.51 | $194,381.18 | |
| 7/20/2015 | James Stambaugh | VP | Sell | 12,000 | $30.52 | $366,240.00 | |
| 7/15/2015 | Lisa D Earnhardt | CEO | Sell | 19,318 | $29.62 | $572,199.16 | |
| 6/15/2015 | Lisa D Earnhardt | CEO | Sell | 19,318 | $29.30 | $566,017.40 | |
| 5/8/2015 | James Stambaugh | VP | Sell | 2,785 | $23.87 | $66,477.95 | |
| 4/13/2015 | Amy Wolbeck | VP | Sell | 16,000 | $26.25 | $420,000.00 | |
| 4/1/2015 | James Stambaugh | VP | Sell | 8,343 | $25.50 | $212,746.50 | |
| 3/16/2015 | Lisa D Earnhardt | Insider | Sell | 19,318 | $23.56 | $455,132.08 | |
| 3/11/2015 | Amy Wolbeck | VP | Sell | 8,000 | $23.06 | $184,480.00 | |
| 3/9/2015 | James Stambaugh | VP | Sell | 8,343 | $23.02 | $192,055.86 | |
| 2/17/2015 | Lisa D Earnhardt | Insider | Sell | 19,318 | $22.69 | $438,325.42 | |
| 2/12/2015 | Amy Wolbeck | VP | Sell | 8,000 | $22.12 | $176,960.00 | |
| 2/2/2015 | James Stambaugh | VP | Sell | 8,343 | $20.98 | $175,036.14 | |
| 1/26/2015 | Robert H Binney Jr | VP | Sell | 6,300 | $21.18 | $133,434.00 | |
| 9/11/2014 | Cynthia L Lucchese | Director | Buy | 5,000 | $17.11 | $85,550.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Intersect ENT (NASDAQ:XENT)
Latest Headlines for Intersect ENT (NASDAQ:XENT)
| Source: |
|
| Date | Headline |
|---|
 | Teresa L. Kline Joins Intersect ENT's Board of Directors | Business ... - Business Wire (press release)
www.businesswire.com - July 21 at 8:52 AM |
 | Teresa L. Kline Joins Intersect ENT’s Board of Directors
finance.yahoo.com - July 21 at 8:51 AM |
 | Zacks: Analysts Expect Intersect ENT, Inc. (XENT) Will Announce Quarterly Sales of $22.65 Million
www.americanbankingnews.com - July 20 at 11:54 AM |
| Insider Selling: Intersect ENT, Inc. (NASDAQ:XENT) Insider Sells 20,000 Shares of Stock
www.americanbankingnews.com - July 18 at 7:25 PM |
| Analysts Expect Intersect ENT, Inc. (XENT) to Announce -$0.19 Earnings Per Share
www.americanbankingnews.com - July 18 at 2:42 PM |
| Intersect ENT to Report Second Quarter 2017 Financial Results
www.businesswire.com - July 15 at 9:46 AM |
| ETFs with exposure to Intersect ENT, Inc. : July 12, 2017
finance.yahoo.com - July 13 at 11:17 AM |
| Intersect ENT, Inc. (NASDAQ:XENT) CFO Sells $348,855.30 in Stock
www.americanbankingnews.com - July 12 at 8:17 PM |
| Intersect ENT, Inc. (XENT) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - July 9 at 6:38 PM |
 | Commit To Buy Intersect ENT At $22.50, Earn 15.7% Annualized Using Options
www.nasdaq.com - July 8 at 8:54 AM |
| ETFs with exposure to Intersect ENT, Inc. : June 27, 2017
finance.yahoo.com - June 28 at 3:32 AM |
| Intersect ENT, Inc. (XENT) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 27 at 2:56 PM |
| Intersect ENT, Inc. (XENT) Expected to Post Quarterly Sales of $22.65 Million
www.americanbankingnews.com - June 24 at 9:34 AM |
| Zacks: Brokerages Anticipate Intersect ENT, Inc. (XENT) Will Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - June 22 at 11:04 AM |
| Insider Selling: Intersect ENT, Inc. (XENT) Insider Sells 20,000 Shares of Stock
www.americanbankingnews.com - June 19 at 7:20 PM |
| ETFs with exposure to Intersect ENT, Inc. : June 16, 2017
finance.yahoo.com - June 17 at 7:50 AM |
| Intersect ENT, Inc. :XENT-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017
finance.yahoo.com - June 14 at 4:16 PM |
| Financial Survey: Intersect ENT (XENT) vs. VWR Corporation (VWR)
www.americanbankingnews.com - June 13 at 10:18 AM |
| Intersect ENT Inc (XENT) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - June 2 at 6:18 PM |
| Intersect ENT Inc (XENT) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - June 2 at 9:00 AM |
| Zacks: Brokerages Expect Intersect ENT Inc (XENT) Will Announce Quarterly Sales of $22.65 Million
www.americanbankingnews.com - May 31 at 2:50 PM |
| Intersect ENT Inc (XENT) Downgraded by Northland Securities
www.americanbankingnews.com - May 31 at 11:56 AM |
| -$0.19 Earnings Per Share Expected for Intersect ENT Inc (XENT) This Quarter
www.americanbankingnews.com - May 29 at 8:28 AM |
| Intersect ENT Inc (XENT) Short Interest Update
www.americanbankingnews.com - May 29 at 7:06 AM |
| FY2017 EPS Estimates for Intersect ENT Inc Decreased by Leerink Swann (XENT)
www.americanbankingnews.com - May 25 at 7:42 AM |
| Insider Selling: Intersect ENT Inc (XENT) COO Sells 20,000 Shares of Stock
www.americanbankingnews.com - May 23 at 7:46 PM |
 | Intersect ENT (XENT) Announces 01/07/18 PDUFA Date for SINUVA ... - StreetInsider.com
www.streetinsider.com - May 22 at 8:05 AM |
| Intersect ENT Announces PDUFA Date for Office-Based SINUVA™ Steroid Releasing Sinus Implant
finance.yahoo.com - May 22 at 8:05 AM |
| Intersect ENT Inc (XENT) Insider Sells $459,600.00 in Stock
www.americanbankingnews.com - May 16 at 7:32 PM |
| Intersect ENT's (XENT) "Outperform" Rating Reiterated at William Blair
www.americanbankingnews.com - May 13 at 12:32 AM |
| Research Analysts Offer Predictions for Intersect ENT Inc's Q2 2017 Earnings (XENT)
www.americanbankingnews.com - May 12 at 7:50 AM |
| Intersect ENT Inc (XENT) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 8 at 11:28 AM |
| Intersect ENT Inc (XENT) Expected to Announce Quarterly Sales of $22.7 Million
www.americanbankingnews.com - May 5 at 1:38 PM |
| Intersect ENT Inc Expected to Post Q3 2017 Earnings of ($0.24) Per Share (XENT)
www.americanbankingnews.com - May 5 at 10:42 AM |
| Leerink Swann Comments on Intersect ENT Inc's Q2 2017 Earnings (XENT)
www.americanbankingnews.com - May 5 at 7:37 AM |
| Intersect ENT Inc Forecasted to Earn FY2019 Earnings of ($0.02) Per Share (XENT)
www.americanbankingnews.com - May 4 at 7:31 PM |
| Northland Securities Reiterates Outperform Rating for Intersect ENT Inc (XENT)
www.americanbankingnews.com - May 4 at 7:18 AM |
| Intersect ENT's (XENT) "Buy" Rating Reaffirmed at Canaccord Genuity
www.americanbankingnews.com - May 4 at 12:06 AM |
| Intersect ENT Inc (XENT) Given "Buy" Rating at Canaccord Genuity
www.americanbankingnews.com - May 4 at 12:00 AM |
| Noteworthy Wednesday Option Activity: XENT, TGT, QRVO
www.nasdaq.com - May 3 at 7:03 PM |
| Zacks: Brokerages Expect Intersect ENT Inc (XENT) to Announce -$0.21 EPS
www.americanbankingnews.com - May 3 at 6:00 PM |
| Intersect ENT Inc (XENT) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 3 at 4:58 PM |
| Intersect ENT (XENT) Receiving Somewhat Favorable Media Coverage, Report Shows
www.americanbankingnews.com - May 3 at 4:26 PM |
| Edited Transcript of XENT earnings conference call or presentation 2-May-17 8:30pm GMT
finance.yahoo.com - May 3 at 9:37 AM |
| Intersect ENT Inc (XENT) Given New $26.00 Price Target at Wedbush
www.americanbankingnews.com - May 3 at 9:06 AM |
| Investor Network: Intersect ENT Inc. to Host Earnings Call
finance.yahoo.com - May 2 at 6:50 PM |
| Intersect ENT Reports First Quarter 2017 Results
finance.yahoo.com - May 2 at 6:50 PM |
 | Intersect ENT reports 1Q loss
marketbeat.com - May 2 at 6:38 PM |
| Intersect ENT (XENT) Earning Somewhat Favorable Media Coverage, Study Finds
www.americanbankingnews.com - April 30 at 8:25 AM |
| Intersect ENT to Present at Bank of America Merrill Lynch 2017 ... - Yahoo Finance
finance.yahoo.com - April 28 at 2:30 AM |
Intersect ENT (XENT) Chart for Saturday, July, 22, 2017
